Modular platform for rapid vaccine development against IBV variants
A scalable modular vaccine platform for poultry, enabling cost-efficient, rapid updates against emerging IBV variants without egg-based production. Supports mass vaccination through spray, drinking water, and in ovo administration with improved safety and cross-protective efficacy.
Overview
The modular vaccine platform is designed to address the challenges of developing vaccines for Infectious Bronchitis Virus (IBV) in poultry. By utilizing a "plug-and-play" architecture, this solution allows for rapid adaptation to new IBV variants, avoiding the traditional reliance on egg-based production. The platform displays antigens on engineered nanoparticles, which can be formulated with alum for prolonged antigen exposure and flagellin as a TLR5 agonist to enhance immune responses. This system is compatible with scalable heterologous expression systems, ensuring high-volume, cost-efficient manufacturing.
Technical specifications
- Modular architecture: Allows swift updates of antigens, enhancing adaptability to emerging virus variants.
- Alum and flagellin integration: Provides sustained antigen release and potent immune enhancement.
- Scalable production: Compatible with E. coli and eukaryotic expression systems.
- Administration flexibility: Optimized for spray, drinking water, and in ovo delivery.
- Applications: Designed for mass vaccination of poultry, improving safety, durability, and cross-protective efficacy against IBV.
Technology readiness level
The technology is currently at TRL 4, with successful safety and immunogenicity demonstrated in animal models. It is undergoing further validation phases to finalize scalable production parameters and support GMP transition.
About Eureka Nanobioengineering
Eureka Nanobioengineering is an Argentina-based biotechnology company that has developed the NBMods platform, a programmable protein-assembly system designed to create multifunctional nanobiodevices. By utilizing rational protein design, the company engineers viral proteins into self-assembling, homogeneous, monodisperse scaffolds. These scaffolds can be fused with various functional cargoes—such as antigens, adjuvants, or reporters—enabling a modular, Lego-like approach to build precise, multivalent particles with controlled topology and orientation. This architecture allows for combinatorial design, facilitating the creation of customized, stable, and cost-effective biological tools while bypassing traditional manufacturing bottlenecks.
The company operates a B2B model, providing platform access for co-development, licensing of lead assets, and strategic partnerships with pharmaceutical firms to accelerate development pipelines. Their technology addresses needs across detection, prevention, and treatment, with current applications including diagnostics, next-generation vaccine platforms, and immunotherapies for neurodegenerative diseases. By enabling rapid, on-demand formulation updates, Eureka seeks to improve global health outcomes through a One Health approach, providing scalable and adaptable solutions for infectious diseases and pandemic preparedness.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.